MCID: CLR003
MIFTS: 55

Clear Cell Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Clear Cell Adenocarcinoma

MalaCards integrated aliases for Clear Cell Adenocarcinoma:

Name: Clear Cell Adenocarcinoma 12 15
Mesonephroma 12 44 73
Water-Clear Cell Adenocarcinoma 12 73
Adenocarcinoma, Clear Cell 44 73
Mesonephroid Clear Cell Carcinoma 12
Water-Clear Cell Carcinoma 12
Adenocarcinoma Clear Cell 55
Mesonephroma, Malignant 12
Malignant Mesonephroma 12
Wolffian Duct Neoplasm 12
Mesonephric Tumor 73

Classifications:



External Ids:

Disease Ontology 12 DOID:4468

Summaries for Clear Cell Adenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells which have clear cytoplasm.

MalaCards based summary : Clear Cell Adenocarcinoma, also known as mesonephroma, is related to urethra clear cell adenocarcinoma and ovarian clear cell adenocarcinoma. An important gene associated with Clear Cell Adenocarcinoma is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Developmental Biology and Endometrial cancer. The drugs Carboplatin and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include cervix, ovary and colon, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Clear-cell adenocarcinoma is a type of adenocarcinoma that shows clear... more...

Related Diseases for Clear Cell Adenocarcinoma

Diseases related to Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 169)
# Related Disease Score Top Affiliating Genes
1 urethra clear cell adenocarcinoma 34.1 AMACR KLK3 SMAD4
2 ovarian clear cell adenocarcinoma 33.7 ARID1A HNF1B SMAD3
3 clear cell adenofibroma 30.2 ARID1A KRT7
4 endodermal sinus tumor 30.1 KLK3 MUC16
5 urethral diverticulum 30.1 AMACR KLK3 KRT7 PAX8
6 vulva adenocarcinoma 29.9 KRT20 KRT7
7 urethra adenocarcinoma 29.9 AMACR KLK3 SMAD4
8 endosalpingiosis 29.8 KRT7 PAX8
9 ovary adenocarcinoma 29.7 ARID1A HNF1B KRT7
10 ovarian cancer 1 29.6 ARID1A HNF1B KRT7 PAX8
11 nephrogenic adenoma 29.6 AMACR KLK3 KRT7 PAX2 PAX8
12 endocervical adenocarcinoma 29.5 KRT20 KRT7 PAX2 PAX8
13 clear cell renal cell carcinoma 29.4 KRT7 PAX2 PAX8
14 renal cell carcinoma, nonpapillary 28.8 AMACR HNF1B KRT20 KRT7 PAX2 PAX8
15 bladder clear cell adenocarcinoma 12.5
16 bile duct clear cell adenocarcinoma 12.5
17 clear cell adenocarcinoma of the ovary 12.5
18 cervical clear cell adenocarcinoma 12.4
19 endometrial clear cell adenocarcinoma 12.4
20 fallopian tube clear cell adenocarcinoma 12.4
21 uterine ligament clear cell adenocarcinoma 12.2
22 ampulla of vater clear cell adenocarcinoma 12.2
23 bladder tubulo-cystic clear cell adenocarcinoma 12.2
24 bladder papillary clear cell adenocarcinoma 12.2
25 bladder diffuse clear cell adenocarcinoma 12.2
26 diethylstilbestrol syndrome 11.4
27 wolffian duct adenoma 11.3
28 epithelial-myoepithelial carcinoma 11.2
29 multilocular cystic renal neoplasm of low malignant potential 11.2
30 adenocarcinoma 11.1
31 endometriosis 10.6
32 adenofibroma 10.2
33 adenoma 10.2
34 seminal vesicle tumor 10.2 KLK3 KRT7
35 prostate squamous cell carcinoma 10.2 KLK3 KRT7
36 rete testis adenocarcinoma 10.2 KLK3 KRT20
37 oligomeganephronia 10.2 HNF1B PAX2
38 cystic basal cell carcinoma 10.2 KRT20 KRT7
39 hypertrophic scars 10.2 SMAD2 SMAD3
40 transverse colon cancer 10.2 KRT20 KRT7
41 appendix adenocarcinoma 10.2 KRT20 KRT7
42 malignant syringoma 10.2 KRT20 KRT7
43 glandular cystitis 10.1 KRT20 KRT7
44 papillary transitional carcinoma 10.1 KRT20 KRT7
45 eyelid carcinoma 10.1 KRT20 KRT7
46 large intestine adenocarcinoma 10.1 KRT20 KRT7
47 linitis plastica 10.1 KRT20 KRT7
48 lung acinar adenocarcinoma 10.1 KRT20 KRT7
49 small cell carcinoma of the bladder 10.1 KRT20 KRT7
50 adenoid squamous cell carcinoma 10.1 KRT20 KRT7

Graphical network of the top 20 diseases related to Clear Cell Adenocarcinoma:



Diseases related to Clear Cell Adenocarcinoma

Symptoms & Phenotypes for Clear Cell Adenocarcinoma

GenomeRNAi Phenotypes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 29)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.87 SMAD4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.87 SMAD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.87 ARID1A
4 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.87 HNF1B
5 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.87 PAX8
6 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.87 ARID1A
7 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.87 ARID1A
8 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.87 HNF1B
9 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.87 HNF1B
10 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.87 ARID1A
11 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.87 ARID1A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-195 9.87 SMAD4
13 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.87 SMAD4
14 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.87 HNF1B
15 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.87 PAX8 SMAD4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.87 PAX8
17 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.87 PAX8
18 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.87 SMAD4
19 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.87 ARID1A HNF1B PAX8 SMAD4
20 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.87 SMAD4
21 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.87 HNF1B
22 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.87 HNF1B
23 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.87 SMAD4
24 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.87 ARID1A SMAD4
25 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.87 SMAD4
26 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.87 HNF1B
27 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.87 HNF1B
28 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.87 PAX8 SMAD4
29 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.87 PAX8

MGI Mouse Phenotypes related to Clear Cell Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.08 ARID1A KRT7 PAX2 PAX8 PTHLH SMAD2
2 homeostasis/metabolism MP:0005376 10.02 AMACR ARID1A HNF1B KRT7 PAX8 PTHLH
3 endocrine/exocrine gland MP:0005379 10.01 ARID1A HNF1B PAX2 PAX8 PTHLH SMAD2
4 embryo MP:0005380 9.98 ARID1A HNF1B PAX2 PAX8 SMAD2 SMAD3
5 craniofacial MP:0005382 9.93 ARID1A PAX8 PTHLH SMAD2 SMAD3 SMAD4
6 liver/biliary system MP:0005370 9.8 AMACR HNF1B PTHLH SMAD2 SMAD3 SMAD4
7 renal/urinary system MP:0005367 9.7 HNF1B KRT7 PAX2 PAX8 PTHLH SMAD3
8 neoplasm MP:0002006 9.65 ARID1A PTHLH SMAD2 SMAD3 SMAD4
9 reproductive system MP:0005389 9.5 ARID1A PAX2 PAX8 PTHLH SMAD2 SMAD3
10 vision/eye MP:0005391 9.1 ARID1A PAX2 PAX8 PTHLH SMAD2 SMAD3

Drugs & Therapeutics for Clear Cell Adenocarcinoma

Drugs for Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
2
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
4
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
5
Lenograstim Approved, Investigational Phase 3,Phase 1 135968-09-1
6
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
7
Epirubicin Approved Phase 3 56420-45-2 41867
8
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
9
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
10
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
11
Olaparib Approved Phase 2, Phase 3,Phase 3 763113-22-0 23725625
12
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60700
13
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
14
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
15
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
16
Cediranib Investigational Phase 2, Phase 3,Phase 3 288383-20-0 9933475
17
Maleic acid Experimental Phase 2, Phase 3,Phase 3 110-16-7 444266
18 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
19 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
20 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
21 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
22 Antimetabolites Phase 3,Phase 2,Phase 1
23 Immunoglobulin G Phase 3,Phase 2,Phase 1
24 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
25 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
26 Antibodies Phase 3,Phase 2,Phase 1
27 Immunoglobulins Phase 3,Phase 2,Phase 1
28 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
29 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
30 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
31 Antimitotic Agents Phase 3,Phase 2,Phase 1
32 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1,Not Applicable
33 Mitogens Phase 3,Phase 2,Phase 1
34 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
35 Adjuvants, Immunologic Phase 3,Phase 1
36 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
37 Antiviral Agents Phase 3,Phase 2,Phase 1
38 Anti-Infective Agents Phase 3,Phase 2,Phase 1
39 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
40 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
41 topoisomerase I inhibitors Phase 2, Phase 3
42 Carotenoids Phase 3
43 Micronutrients Phase 3,Not Applicable
44 Trace Elements Phase 3,Not Applicable
45 Hypoglycemic Agents Phase 2, Phase 3
46 taxane Phase 3,Not Applicable
47
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
48
Vinblastine Approved Phase 2 865-21-4 241903 13342
49
Sunitinib Approved, Investigational Phase 2,Not Applicable 557795-19-4, 341031-54-7 5329102
50
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563

Interventional clinical trials:

(show top 50) (show all 104)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
3 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
4 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
5 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
6 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
7 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
8 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
9 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
10 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
11 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
12 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
13 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
14 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
15 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
16 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
17 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
18 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
19 Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer Active, not recruiting NCT00411138 Phase 3 cisplatin;carboplatin;Paclitaxel
20 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
21 Immunochemotherapy for Metastatic Renal Cell Carcinoma Unknown status NCT00226798 Phase 2 Capecitabine (Xeloda)
22 Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer Unknown status NCT01100359 Phase 2 carboplatin;liposome-encapsulated doxorubicin citrate
23 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Completed NCT01824615 Phase 2 Sunitinib
24 A Study of ENMD-2076 in Ovarian Clear Cell Cancers Completed NCT01914510 Phase 2 ENMD-2076
25 AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib Completed NCT00467025 Phase 2 AMG 386;Sorafenib;AMG 386 placebo IV
26 Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney Completed NCT00853021 Phase 2
27 Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
28 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
29 Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer Completed NCT00719264 Phase 2 RAD001(everolimus);interferon alfa-2a;bevacizumab
30 LBH589 Treatment for Refractory Clear Cell Renal Carcinoma Completed NCT00550277 Phase 2 LBH589
31 Sunitinib in Metastatic Renal Cancer Completed NCT01034878 Phase 2 Sunitinib
32 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01011933 Phase 2 Selumetinib
33 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
34 High-dose Bevacizumab in Advanced Renal Carcinoma Patients Completed NCT00455975 Phase 2 Bevacizumab
35 Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer Completed NCT00002562 Phase 2 paclitaxel
36 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
37 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2 Cediranib Maleate
38 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
39 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
40 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00888173 Phase 2 Brivanib Alaninate
41 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
42 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
43 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide
44 S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer Completed NCT00003127 Phase 2 amifostine trihydrate;carboplatin;paclitaxel
45 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
46 Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer Completed NCT00770185 Phase 2 ridaforolimus
47 Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer Completed NCT00113373 Phase 2 lapatinib ditosylate
48 Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Recruiting NCT02866370 Phase 2 Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
49 A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas Recruiting NCT03405454 Phase 2 durvalumab;standard chemotherapy
50 BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas Recruiting NCT03355976 Phase 2 Nivolumab;Ipilimumab

Search NIH Clinical Center for Clear Cell Adenocarcinoma

Cochrane evidence based reviews: mesonephroma

Genetic Tests for Clear Cell Adenocarcinoma

Anatomical Context for Clear Cell Adenocarcinoma

MalaCards organs/tissues related to Clear Cell Adenocarcinoma:

41
Cervix, Ovary, Colon, Prostate, T Cells, Kidney, Lymph Node

Publications for Clear Cell Adenocarcinoma

Articles related to Clear Cell Adenocarcinoma:

(show top 50) (show all 458)
# Title Authors Year
1
Ovarian Clear Cell Adenofibroma of Low Malignant Potential Developing Into Clear Cell Adenocarcinoma. ( 29551085 )
2018
2
Synchronous occurrence of primary right ovarian endometrioid adenocarcinoma and primary left ovarian clear cell adenocarcinoma: A case report. ( 29979406 )
2018
3
Clear Cell Adenocarcinoma Arising from Endometriosis in the Groin: Wide Resection and Reconstruction with a Fascia Lata Tensor Muscle Skin Flap. ( 29805826 )
2018
4
Unusual Features of Clear Cell Adenocarcinoma of the Female Urethra: A Case Report and Literature Review. ( 29977425 )
2018
5
Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma with fetal gut differentiation: a rare case report and literature review. ( 29933751 )
2018
6
Clear cell adenocarcinoma of female urethra: A case report. ( 29888186 )
2018
7
Clear cell adenocarcinoma of the urethra with inguinal lymph node metastases: A rare case report and review of literature. ( 29516944 )
2018
8
Follow-up of Patients with Clear-Cell Adenocarcinoma of the Vagina and Cervix. ( 29719188 )
2018
9
Primary clear cell adenocarcinoma of the pancreas: a case report and literature update. ( 30532559 )
2018
10
Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response. ( 30202792 )
2018
11
Fairly rare clear cell adenocarcinoma mimicking liver cancer: a case report. ( 30117003 )
2018
12
Cervical clear cell adenocarcinoma with an exceptionally low proliferation index: Report of a case. ( 29326971 )
2018
13
Three cases of clear-cell adenocarcinoma arising from endometrioma during hormonal treatments. ( 29998468 )
2018
14
Early stage clear cell adenocarcinoma of the colon examined in detail with image-enhanced endoscopy: a case report. ( 30062544 )
2018
15
Clear Cell Adenocarcinoma of the Urethra in Women: Distinctive MRI Findings for Differentiation From Nonadenocarcinoma and Non-Clear Cell Adenocarcinoma of the Urethra. ( 28140610 )
2017
16
Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up. ( 28689666 )
2017
17
Clear cell adenocarcinoma of the cervix in second generation young women who are without maternal exposure to diethylstilbestrol: A case report. ( 28275694 )
2017
18
Skin metastases in ovarian clear cell adenocarcinoma: a case report and a review of the literature. ( 29184869 )
2017
19
Clear cell adenocarcinoma of cervix in 1-year-old girl without in utero exposure to diethylstilbestrol: an uncommon tumour at an uncommon age and site. ( 28302659 )
2017
20
Clear Cell Adenocarcinoma of Female Urethra. ( 28892907 )
2017
21
The Prostate in Female? Clear Cell Adenocarcinoma in a Female Urethral Diverticulum. ( 27789300 )
2017
22
Clear Cell Adenocarcinoma of the Female Urethra, Mimicking Cystocele. ( 28280687 )
2017
23
Vesical clear cell adenocarcinoma arising from endometriosis: A mullerian tumor, indistinguishable from ovarian clear cell adenocarcinoma. ( 27660815 )
2016
24
A clear cell adenocarcinoma of the gallbladder with hepatoid differentiation: case report and review of literature. ( 27703378 )
2016
25
Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary. ( 27699033 )
2016
26
Clear Cell Adenocarcinoma of the Female Urethra: Four Case Presentations of a Clinical and Pathological Entity Requiring Radical Surgery. ( 26807736 )
2016
27
Clear Cell Adenocarcinoma of the Lung Mimicking Clear Cell Renal Cell Carcinoma. ( 29772138 )
2016
28
Clear cell adenocarcinoma of the cervix in a ten-year-old girl without prenatal diethylstilbestrol exposure. ( 27549741 )
2016
29
Clear cell adenocarcinoma arising from adenomyotic cyst: A case report and literature review. ( 26530432 )
2015
30
Combined benign Brenner tumor and clear cell adenocarcinoma of the ovary. ( 26150073 )
2015
31
Low Expression of S100P Is Associated With Poor Prognosis in Patients With Clear Cell Adenocarcinoma of the Ovary. ( 26397155 )
2015
32
Primary Fallopian Tube Clear Cell Adenocarcinoma in Pregnancy: Case Presentation and Review of the Literature. ( 26090245 )
2015
33
Successful radiotherapy for repeated recurrent uterine clear cell adenocarcinoma. ( 26310385 )
2015
34
High-dose-rate brachytherapy - a novel treatment approach for primary clear cell adenocarcinoma of male urethra. ( 26207115 )
2015
35
Clear cell adenocarcinoma of the urethra: review of the literature. ( 25685552 )
2015
36
A rare case of primary clear-cell adenocarcinoma of the bladder arising from bladder endometriosis. ( 25642923 )
2015
37
Late recurrence in a case of vaginal clear cell adenocarcinoma unrelated to transplacental diethylstilbestrol exposure. ( 26905123 )
2015
38
Clear Cell Adenocarcinoma Arising from Adenofibroma in a Patient with Endometriosis of the Ovary. ( 26498012 )
2015
39
Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma. ( 25658832 )
2015
40
Clear cell adenocarcinoma of the bladder with intravesical cervical invasion. ( 26109625 )
2015
41
Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice. ( 25398420 )
2014
42
Mass Spectrometric Analysis of the Phosphorylation Levels of the SWI/SNF Chromatin Remodeling/Tumor Suppressor Proteins ARID1A and Brg1 in Ovarian Clear Cell Adenocarcinoma Cell Lines. ( 25083560 )
2014
43
Non-diethylstilbestrol exposed vaginal clear cell adenocarcinoma has a common molecular profile with ovarian clear cell adenocarcinoma: A case report. ( 26082939 )
2014
44
Primary non-clear-cell adenocarcinoma of the vagina in a diethylstilbestrol exposed woman. ( 24690973 )
2014
45
Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma simulating fetal gut in a postmenopausal woman. ( 24707459 )
2014
46
Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary. ( 25010038 )
2014
47
Therapy of a clear cell adenocarcinoma of unknown primary arising in the abdominal wall after cesarean section and after hysterectomy. ( 25301100 )
2014
48
A case of clear cell adenocarcinoma arising from endometriosis of the rectum treated by laparoscopic surgery. ( 25460452 )
2014
49
Clear cell adenocarcinoma present exclusively within endometrial polyp: report of two cases. ( 24817975 )
2014
50
Clear Cell Adenocarcinoma of the Urethra: 18F-FDG PET/CT Imaging. ( 25140553 )
2014

Variations for Clear Cell Adenocarcinoma

Copy number variations for Clear Cell Adenocarcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 218693 7 116312458 116438439 Amplification MET Clear cell adenocarcinoma
2 266962 Y 174481503 174538309 Duplication AZF Clear cell adenocarcinoma

Expression for Clear Cell Adenocarcinoma

Search GEO for disease gene expression data for Clear Cell Adenocarcinoma.

Pathways for Clear Cell Adenocarcinoma

Pathways related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.35 HNF1B KRT20 KRT7 SMAD2 SMAD3 SMAD4
2
Show member pathways
12.64 KLK3 PAX8 SMAD2 SMAD3 SMAD4
3
Show member pathways
12.62 ARID1A SMAD2 SMAD3 SMAD4
4 12.6 KLK3 PAX8 SMAD2 SMAD3 SMAD4
5
Show member pathways
12.31 HNF1B SMAD2 SMAD3 SMAD4
6
Show member pathways
12.14 HNF1B PTHLH SMAD2 SMAD3 SMAD4
7
Show member pathways
12.09 SMAD2 SMAD3 SMAD4
8 12.05 SMAD2 SMAD3 SMAD4
9 12.01 SMAD2 SMAD3 SMAD4
10 11.96 SMAD2 SMAD3 SMAD4
11
Show member pathways
11.95 SMAD2 SMAD3 SMAD4
12 11.95 SMAD2 SMAD3 SMAD4
13 11.93 SMAD2 SMAD3 SMAD4
14 11.93 SMAD2 SMAD3 SMAD4
15 11.93 PAX2 SMAD2 SMAD3 SMAD4
16
Show member pathways
11.91 SMAD2 SMAD3 SMAD4
17 11.78 SMAD2 SMAD3 SMAD4
18 11.76 SMAD2 SMAD3 SMAD4
19
Show member pathways
11.74 SMAD2 SMAD3 SMAD4
20 11.72 KLK3 SMAD3 SMAD4
21 11.68 SMAD2 SMAD3 SMAD4
22
Show member pathways
11.62 SMAD2 SMAD3 SMAD4
23 11.61 SMAD2 SMAD3 SMAD4
24 11.57 SMAD2 SMAD3 SMAD4
25 11.57 SMAD2 SMAD3 SMAD4
26 11.56 SMAD2 SMAD3 SMAD4
27
Show member pathways
11.53 SMAD2 SMAD3 SMAD4
28
Show member pathways
11.48 SMAD2 SMAD3 SMAD4
29 11.4 SMAD2 SMAD3 SMAD4
30 11.32 SMAD2 SMAD3 SMAD4
31
Show member pathways
11.28 SMAD2 SMAD3 SMAD4
32 10.97 SMAD3 SMAD4
33 10.97 SMAD2 SMAD3 SMAD4
34 10.82 PAX2 PAX8
35 10.73 SMAD2 SMAD3 SMAD4
36 10.41 SMAD2 SMAD3 SMAD4
37 10.05 SMAD2 SMAD3 SMAD4

GO Terms for Clear Cell Adenocarcinoma

Cellular components related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear chromatin GO:0000790 9.62 ARID1A SMAD2 SMAD3 SMAD4
2 transcription factor complex GO:0005667 9.56 HNF1B SMAD2 SMAD3 SMAD4
3 activin responsive factor complex GO:0032444 9.16 SMAD2 SMAD4
4 heteromeric SMAD protein complex GO:0071144 8.96 SMAD2 SMAD3
5 SMAD protein complex GO:0071141 8.8 SMAD2 SMAD3 SMAD4

Biological processes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 48)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.95 ARID1A HNF1B PAX2 PAX8 SMAD2 SMAD3
2 kidney development GO:0001822 9.85 HNF1B PAX8 SMAD4
3 anterior/posterior pattern specification GO:0009952 9.84 HNF1B SMAD2 SMAD4
4 transforming growth factor beta receptor signaling pathway GO:0007179 9.83 SMAD2 SMAD3 SMAD4
5 SMAD protein signal transduction GO:0060395 9.79 SMAD2 SMAD3 SMAD4
6 positive regulation of epithelial to mesenchymal transition GO:0010718 9.75 SMAD2 SMAD3 SMAD4
7 branching involved in ureteric bud morphogenesis GO:0001658 9.74 PAX2 PAX8 SMAD4
8 pancreas development GO:0031016 9.7 HNF1B SMAD2
9 thyroid gland development GO:0030878 9.7 PAX8 SMAD3
10 adrenal gland development GO:0030325 9.7 SMAD2 SMAD3
11 embryonic pattern specification GO:0009880 9.69 SMAD2 SMAD3
12 signal transduction involved in regulation of gene expression GO:0023019 9.69 SMAD2 SMAD3
13 osteoblast development GO:0002076 9.69 PTHLH SMAD3
14 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.68 PAX2 PAX8
15 activin receptor signaling pathway GO:0032924 9.68 SMAD2 SMAD3
16 urogenital system development GO:0001655 9.68 PAX2 PAX8
17 secondary palate development GO:0062009 9.67 SMAD2 SMAD4
18 mesonephros development GO:0001823 9.67 PAX2 PAX8
19 nodal signaling pathway GO:0038092 9.65 SMAD2 SMAD3
20 primary miRNA processing GO:0031053 9.65 SMAD2 SMAD3
21 embryonic foregut morphogenesis GO:0048617 9.65 SMAD2 SMAD3
22 pericardium development GO:0060039 9.64 SMAD2 SMAD3
23 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003337 9.63 PAX2 PAX8
24 mesonephric tubule development GO:0072164 9.63 HNF1B PAX8
25 developmental growth GO:0048589 9.63 SMAD2 SMAD3 SMAD4
26 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072307 9.62 PAX2 PAX8
27 metanephric epithelium development GO:0072207 9.61 PAX2 PAX8
28 metanephric distal convoluted tubule development GO:0072221 9.61 PAX2 PAX8
29 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.61 SMAD2 SMAD3 SMAD4
30 metanephric nephron tubule formation GO:0072289 9.6 PAX2 PAX8
31 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072108 9.59 PAX2 PAX8
32 regulation of transforming growth factor beta2 production GO:0032909 9.58 SMAD3 SMAD4
33 nephric duct formation GO:0072179 9.56 HNF1B PAX2
34 gastrulation GO:0007369 9.56 ARID1A SMAD2 SMAD3 SMAD4
35 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 9.55 PAX2 PAX8
36 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 9.54 PAX2 PAX8
37 SMAD protein complex assembly GO:0007183 9.54 SMAD2 SMAD3 SMAD4
38 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 9.52 PAX2 PAX8
39 paraxial mesoderm morphogenesis GO:0048340 9.51 SMAD2 SMAD3
40 pronephros development GO:0048793 9.5 HNF1B PAX2 PAX8
41 positive regulation of metanephric DCT cell differentiation GO:2000594 9.49 PAX2 PAX8
42 pronephric field specification GO:0039003 9.48 PAX2 PAX8
43 endoderm development GO:0007492 9.46 HNF1B SMAD2 SMAD3 SMAD4
44 regulation of binding GO:0051098 9.13 SMAD2 SMAD3 SMAD4
45 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 8.8 HNF1B PAX2 PAX8
46 positive regulation of transcription by RNA polymerase II GO:0045944 10.11 HNF1B PAX2 PAX8 SMAD2 SMAD3 SMAD4
47 negative regulation of transcription by RNA polymerase II GO:0000122 10.08 ARID1A HNF1B SMAD2 SMAD3 SMAD4
48 negative regulation of cell proliferation GO:0008285 10 PTHLH SMAD2 SMAD3 SMAD4

Molecular functions related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.89 HNF1B PAX8 SMAD2 SMAD3 SMAD4
2 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.87 ARID1A HNF1B PAX2 PAX8 SMAD2 SMAD3
3 protein heterodimerization activity GO:0046982 9.84 HNF1B SMAD2 SMAD3 SMAD4
4 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.81 PAX8 SMAD2 SMAD3 SMAD4
5 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.7 SMAD2 SMAD3 SMAD4
6 enhancer binding GO:0035326 9.46 SMAD2 SMAD3
7 co-SMAD binding GO:0070410 9.43 SMAD2 SMAD3
8 I-SMAD binding GO:0070411 9.4 SMAD2 SMAD4
9 primary miRNA binding GO:0070878 9.37 SMAD2 SMAD3
10 transcription regulatory region DNA binding GO:0044212 9.35 HNF1B PAX2 PAX8 SMAD3 SMAD4
11 R-SMAD binding GO:0070412 9.33 SMAD2 SMAD3 SMAD4
12 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 9.26 SMAD2 SMAD3
13 proximal promoter sequence-specific DNA binding GO:0000987 8.92 HNF1B PAX2 SMAD3 SMAD4
14 DNA binding GO:0003677 10.02 ARID1A HNF1B PAX2 PAX8 SMAD2 SMAD3

Sources for Clear Cell Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....